SCHEMBL387423

SCHEMBL387423

CCCCC[CH]SCCC

nearest known ligand 0.40

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.40
FAAH O00519 2/20 0.36
TRPV1 Q8NER1 2/20 0.36
THRB P10828 1/20 0.35
DNM1 Q05193 3/20 0.33
ALDH1A1 P00352 2/20 0.33
EP300 Q09472 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5143912 0.97 TSHR (0.44) TSHRFAAHTRPV1THRBDNM1
SCHEMBL199113 0.97 TSHR (0.44) TSHRFAAHTRPV1THRBDNM1
SCHEMBL5071796 0.97 TSHR (0.44) TSHRFAAHTRPV1THRBDNM1
SCHEMBL386144 0.92
SCHEMBL201111 0.90 TSHR (0.40) TSHRFAAHTRPV1THRBDNM1
SCHEMBL198776 0.90 TSHR (0.40) TSHRFAAHTRPV1THRBDNM1
SCHEMBL198595 0.87 TSHR (0.44) TSHRFAAHTRPV1THRBDNM1
SCHEMBL198438 0.87 TSHR (0.44) TSHRFAAHTRPV1THRBDNM1
SCHEMBL199898 0.87 TSHR (0.44) TSHRFAAHTRPV1THRBDNM1
SCHEMBL199163 0.87 TSHR (0.44) TSHRFAAHTRPV1THRBDNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101650-B2 Method for treating a immunology-related disease DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-24 US disclosed
US-8067396-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2011-11-29 US disclosed
US-7910617-B2 Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound SANKYO COMPANY, LIMITED (JP) 2011-03-22 US disclosed
US-7718377-B2 Insulin resistance curative and method of screening the same KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2010-05-18 US disclosed
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2010-02-11 US disclosed
US-20090326038-A1 Method for treating a immunology-related disease SANKYO COMPANY, LIMITED (JP) 2009-12-31 US disclosed
US-7638551-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2009-12-29 US disclosed
US-7557123-B2 Heterocyclic compound and medicinal use thereof KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2009-07-07 US disclosed
EP-1471054-B1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE DAIICHI SANKYO CO LTD (JP) 2009-07-01 EP disclosed
US-7301029-B2 Bipyridine Derivatives FUJIFILM FINECHEMICALS CO., LTD. (JP) 2007-11-27 US disclosed
US-5155113-A Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-10-13 US disclosed
EP-0436902-A1 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-07-17 EP disclosed
US-4983609-A Anticancer agents OTSUKA PHARMACEUTICAL (JP) 1991-01-08 US disclosed
EP-0192242-B1 SUBSTITUTED AMINOPHENYLUREA DERIVATIVES TOKUYAMA SODA KABUSHIKI KAISHA (JP) 1990-11-07 EP disclosed
US-4864021-A ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-09-05 US disclosed
EP-0323441-A2 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-07-05 EP disclosed
US-4803223-A ANTITUMOR AGENTS TOKUYAMA SODA KABUSHIKI KAISHA (JP) 1989-02-07 US disclosed
EP-0192242-A1 Substituted aminophenylurea derivatives TOKUYAMA SODA KABUSHIKI KAISHA (JP) 1986-08-27 EP disclosed
EP-0180897-A2 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-14 EP disclosed
EP-0180188-A2 A composition for increasing the anti-cancer activity of an anti-cancer compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326038-A1 Method for treating a immunology-related disease C3AR1, HRH3, HRH2 TSHR 241/4885FAAH 922/4885TRPV1 2931/4885
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof PHOSPHO1, ADH1C, ADH1A TSHR 744/4885FAAH 967/4885TRPV1 4532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.